Literature DB >> 8923320

Effect of the enantiomers of flurbiprofen, ibuprofen, and ketoprofen on intestinal permeability.

N M Davies1, M R Wright, A S Russell, F Jamali.   

Abstract

Numerous studies have demonstrated that the administration of nonsteroidal anti-inflammatory drugs (NSAIDs) increases small intestinal permeability, and this has been suggested to be a prerequisite to enteropathy. It is believed that the inhibitory effect of chiral NSAIDs on the synthesis of prostaglandins and hence their efficacy and toxicity are mainly due to the S enantiomer. Using the urinary excretion of [51Cr]-EDTA, we have investigated the effects of three nonsteroidal anti-inflammatory drugs (flurbiprofen, ibuprofen, and ketoprofen) on small intestinal permeability in rats. Single doses of each NSAID were administered orally as either the racemate or the R or S enantiomer, the enantiomer dose being half that of the racemate. Each treatment caused a significant increase in intestinal permeability above that seen in untreated animals. The R enantiomers of all three NSAIDs increased small intestinal permeability significantly above base line, which was expected for (R)-ketoprofen and (R)-ibuprofen due to substantial chiral R to S inversion. The intestinal permeability for (R)-flurbiprofen, although minimal and likely due to 10% inversion, may also suggest prostaglandin-independent involvement. Furthermore, (S)-flurbiprofen, used at one-half the dose of the racemate, increased permeability to a similar magnitude as the racemate. This observation was similar to that previously reported for etodolac. A stereochemically pure enantiomer does not necessarily offer a safer alternative than its racemic form.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8923320     DOI: 10.1021/js960276y

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

Review 1.  Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach.

Authors:  N M Davies; N M Skjodt
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

2.  Influence of prolonged exposure of a short half life non-steroidal anti-inflammatory drugs on gastrointestinal safety.

Authors:  Corinne Campanella; Fakhreddin Jamali
Journal:  Inflammopharmacology       Date:  2009-07-08       Impact factor: 4.473

3.  Mechanisms involved in the attenuation of intestinal toxicity induced by (S)-(+)-ketoprofen in re-fed rats.

Authors:  Ana I Nieto; Francesc Cabré; Francisco J Moreno; Catalina Alarcón de la Lastra
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

Review 4.  Clinical pharmacokinetics of dexketoprofen.

Authors:  M J Barbanoj; R M Antonijoan; I Gich
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Influence of dosage form on the gastroenteropathy of flurbiprofen in the rat: evidence of shift in the toxicity site.

Authors:  N M Davies; F Jamali
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

6.  Gastric toxicity of racemic ketoprofen and its enantiomers in rat: oxygen radical generation and COX-expression.

Authors:  C Alarcón de la Lastra; A Nieto; M J Martín; F Cabré; J M Herrerías; V Motilva
Journal:  Inflamm Res       Date:  2002-02       Impact factor: 4.575

7.  Enantiomers of flurbiprofen can distinguish key pathophysiological steps of NSAID enteropathy in the rat.

Authors:  T Mahmud; S Somasundaram; G Sigthorsson; R J Simpson; S Rafi; R Foster; I A Tavares; A Roseth; A J Hutt; M Jacob; J Pacy; D L Scott; J M Wrigglesworth; I Bjarnason
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

8.  Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch.

Authors:  Waheed Asghar; Elliot Pittman; Fakhreddin Jamali
Journal:  Daru       Date:  2015-11-14       Impact factor: 3.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.